ONCORUS
Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.
ONCORUS
Industry:
Biotechnology Medical Therapeutics
Founded:
2015-04-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.oncorus.com
Total Employee:
11+
Status:
Active
Contact:
(857)320-6402
Total Funding:
218.49 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Current Advisors List
Board_member
Current Employees Featured
Lorena Lerner Vice President Research @ Oncorus
Vice President Research
2019-01-01
Theodore T. Ashburn President & CEO @ Oncorus
President & CEO
2018-07-01
John McCabe Chief Financial Officer @ Oncorus
Chief Financial Officer
2017-10-01
Kenneth Greenberg Co-Founder @ Oncorus
Co-Founder
2015-04-01
Steve Harbin COO and Chief of Staff @ Oncorus
COO and Chief of Staff
Scott A. Canute Director @ Oncorus
Director
2020-12-01
John Goldberg Chief Medical Officer @ Oncorus
Chief Medical Officer
2022-02-01
Founder
Stock Details
Investors List
K2 HealthVentures
K2 HealthVentures investment in Post-IPO Debt - Oncorus
Arkin Bio Ventures
Arkin Bio Ventures investment in Series B - Oncorus
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - Oncorus
Perceptive Advisors
Perceptive Advisors investment in Series B - Oncorus
Celgene
Celgene investment in Series B - Oncorus
Deerfield
Deerfield investment in Series B - Oncorus
Sphera Funds Management
Sphera Funds Management investment in Series B - Oncorus
Shinhan Private Equity
Shinhan Private Equity investment in Series B - Oncorus
SV Investment Partners
SV Investment Partners investment in Series B - Oncorus
UTC Investment Co.
UTC Investment Co. investment in Series B - Oncorus
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-10 | Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer |
| 2022-02-22 | Oncorus Announces Promotion of John Goldberg, M.D. to Chief Medical Officer |
More informations about "Oncorus"
Oncorus - Crunchbase Company Profile & Funding
Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. …See details»
Oncorus Inc (ONCR) Profile - The Globe and Mail
See the company profile for Oncorus Inc (ONCR) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
Oncorus Company Profile | Management and Employees List
Oncorus headquarters are located in 50 Hampshire St Ste 401, Cambridge, Massachusetts, 02139, United States What are Oncorus’s primary industries? Oncorus’s main industries are: …See details»
Oncorus - LinkedIn
Oncorus is focused on realizing the full promise of IV-administered, self-amplifying RNA medicines to transform outcomes for cancer patients. We believe this modality has the …See details»
Oncorus Company Profile - Office Locations, Competitors ... - Craft
May 10, 2022 Oncorus is a biopharmaceutical company focused on developing viral immunotherapies to transform outcomes for cancer patients. Using its two platforms, the …See details»
Oncorus, Inc. Company Profile | Andover, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Oncorus, Inc. of Andover, MA. Get the latest business insights from Dun & Bradstreet.See details»
Working At Oncorus: Company Overview and Culture - Zippia
Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing …See details»
Oncorus - Overview, News & Similar companies | ZoomInfo.com
Jun 2, 2023 Oncorus Announces Workforce Reduction Plan ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company …See details»
Oncorus - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Oncorus . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 6. Number of Board …See details»
Oncorus - Funding, Financials, Valuation & Investors - Crunchbase
Oncorus is registered under the ticker NASDAQ:ONCR . Their stock opened with $15.00 in its Oct 1, 2020 IPO. Oncorus is funded by 19 investors. K2 HealthVentures and Arkin Bio Ventures …See details»
Oncorus Company Profile 2024: Stock Performance & Earnings
Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company …See details»
Oncorus Inc (ONCR) Stock Price and News - The Globe and Mail
Real-time Price Updates for Oncorus Inc (ONCR), along with buy or sell indicators, analysis, charts, historical performance, news and moreSee details»
Governance Oncorus, Inc. - MarketScreener.com
Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The …See details»
Oncorus Announces Workforce Reduction Plan - Yahoo Finance
ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying …See details»
Oncorus - workinbiotech.com
Oncorus is generating next-generation immunotherapies to activate the immune system to target and destroy cancer cells. Oncorus’ approach differs from current therapies that activate not …See details»
Oncorus liquidates a week after shedding workforce - Fierce Biotech
Jun 12, 2023 A week after Oncorus shed pretty much all its staff, the biotech’s board has decided that the game is up and moved to liquidate the RNA-focused company. | A week after …See details»
Facing bankruptcy, Oncorus lays off 'substantially' all staff
Jun 2, 2023 Oncorus was already predicting that the $45 million in cash and equivalents it ended March with would only last until the third quarter of the year. Oncorus is far from the only …See details»
Oncorus - Crunchbase
Oncorus, Avstera Therapeutics, Vor Biopharma, Enliven Therapeutics, Interius BioTherapeutics, and Pinpoint Therapeutics are all involved in the oncology and biotech sector. Avstera …See details»
Oncorus to Present Initial Data from its Ongoing Phase 1 Clinical …
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for …See details»
Oncorus Announces Portfolio Reprioritization to Focus on
Nov 30, 2022 Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains …See details»